Quick Answer
Anika Therapeutics, Inc. reported Gross Profit of $63.81 million for fiscal year 2025.
Anika Therapeutics, Inc. Gross Profit — Annual History
| Fiscal Year | Gross Profit | YoY Change |
|---|---|---|
| 2025 | $63.81M | -16.0% |
| 2024 | $76.00M | -7.9% |
| 2023 | $82.53M | +12.7% |
| 2022 | $73.22M | -11.7% |
| 2021 | $82.94M | +20.2% |
| 2020 | $69.03M | -19.6% |
| 2019 | $85.86M | +15.6% |
| 2018 | $74.28M | — |
Quarterly Gross Profit
| Quarter Ending | Gross Profit | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $15.58M | -19.7% | +8.5% |
| June 30, 2025 | $14.36M | -29.9% | -2.2% |
| March 31, 2025 | $14.68M | -22.6% | -24.4% |
| September 30, 2024 | $19.41M | -22.2% | -5.3% |
| June 30, 2024 | $20.49M | -29.3% | +8.0% |
| March 31, 2024 | $18.98M | -16.9% | -23.9% |
| September 30, 2023 | $24.94M | +9.5% | -13.9% |
| June 30, 2023 | $28.97M | +16.5% | +26.8% |
- Anika Therapeutics, Inc. showed a decrease of -16.0% in Gross Profit compared to the prior fiscal year.
- Over the 2018–2025 period, Anika Therapeutics, Inc.’s gross profit has declined by 14.1% (from $74.28 million to $63.81 million).
- The most recent figure is from Anika Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 3, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: